Incidence of acute myocardial injury and its association with left and right ventricular systolic dysfunction in critically ill COVID-19 patients

Annals of Intensive Care

Table 1 Baseline characteristics and biomarker findings in all patients and stratified by acute myocardial injury

	All patients n = 74	No AMInj n = 13	AMInj n = 60	P value
Age	62.5 (56–72)	60 (55–62)	65 (59–73)	0.030
Sex, male	50 (68%)	5 (39%)	44 (73%)	0.023
BMI, kg/m²	28.7 (25.6–33.5)	27.8 (25.4–35.7)	28.7 (26–32.9)	0.751
SAPS-3	54 (49–62)	53 (49–56)	54.5 (50–63.5)	0.239
SOFA on admission	6 (4–8)	4 (4–6)	7 (4–8)	0.077
SOFA max	10 (7.5–12)	6 (5–6.5)	10.5 (8–12)	<0.001
CFS	3 (2–3)	3 (3–3)	3 (2–3)	0.144
Hypertension	42 (57%)	4 (31%)	38 (63%)	0.031
Diabetes	18 (24%)	2 (15%)	16 (28%)	0.498
Preexisting cardiac disease^a	18 (24%)	3 (23%)	15 (25%)	1
Chronic respiratory disease	14 (19%)	2 (15%)	12 (20%)	1
Chronic renal disease	8 (11%)	0 (0%)	8 (13%)	0.336
Vasopressor days	10 (5–21)	3 (0–5)	13 (7–23)	<0.001
VIS, μg/kg/min^b	4.34 (1.94–7.31)	1.24 (0.38–5.13)	5.04 (1.97–7.6)	0.040
CRRT	14 (19%)	1 (8%)	13 (22%)	0.440
hsTnT max, ng/l	53 (21–127)	12 (10–14)	71 (38–140)	<0.001
Day of peak hsTnT	8 (3–13)	2 (1–5)	10 (3–13)	0.002
NT-proBNP max, ng/l	1960 (755–5618)	760 (210–960)	2665 (870–6830)	<0.001
Day of peak NT-proBNP	4 (2–9)	3 (1–5)	7 (2–10)	0.027
Lactate at admission	1.2 (0.9–1.7)	1.2 (0.9–1.6)	1.3 (0.9–1.7)	0.977
Proportion requiring IMV	69 (93%)	9 (69%)	59 (98%)	0.067
IMV days	14.5 (6.75–25.5)	5 (0–9)	17.5 (8.5–28)	0.001
ICU LOS	17 (8–27.5)	7 (5–13)	19.5 (10.5–28)	0.015
ICU mortality	14 (19%)	1 (8%)	13 (22%)	0.440
30-day mortality	13 (18%)	0 (0%)	13 (22%)	0.107

Acute myocardial injury (AMInj) is defined as an increased hsTnT > 14ng/L and a > 20% absolute change with or without ischaemic symptoms [1]
Data are given as n (%) or median (IQR) unless otherwise indicated
P values refer to No acute myocardial injury vs. acute myocardial injury
SAPS Simplified Acute Physiology Score, SOFA sequential organ failure assessment, VI Vasopressor inotrope score, CRRT continuous renal replacement therapy, hsTnT high sensitivity Troponin T, NT-proBNP N-terminal pro B-type natriuretic peptide, ICU intensive care unit, LOS length of stay, IMV invasive mechanical ventilation
^aDefined as arrythmia, heart failure or ischaemic heart disease
^bCalculated as dopamine dose (μg/kg/min) + dobutamine dose (μg/kg/min) + 100x epinephrine dose (μg/kg/min) + 10x milrinone dose (μg/kg/min) + 10.000x vasopressin dose (U/kg/min) + 100x norepinephrine dose (μg/kg/min) [34]